Sector News

With inversion pushback mounting, Akorn eyes bid for UCB subsidiary

September 12, 2014
Life sciences
The threat of action from lawmakers may have put a damper on pharma’s tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois’ Akorn, which is reportedly looking into a bid for Belgian pharma UCB’s U.S. subsidiary.
 
The Lake Forest pharma is one of a small number of companies exploring a buyout of New Jersey-based Kremers Urban Pharmaceuticals, sources tell Reuters. Back in August, the news service reported that UCB was interested in hiving off the business in a slim-down effort, another pharma trend that’s currently in vogue.
 
With a pickup of Kremers, Akorn could shift its tax domicile to Europe–cutting down its relatively high rate, Reuters says. Akorn, with a market cap of $3.8 billion, will pay an estimated 37% this fiscal year, compared with the industry average of 23%.
 
Kremers, which makes specialty generics products, would also build up Akorn’s own specialty lineup, which includes ophthalmic and injectable offerings. But there may be other suitors on hand as well, with Impax Laboratories, Lupin and Lannett among those for whom Kremers could make an attractive target.
 
U.S. political pressure on companies eyeing tax-fueled deals has been mounting, with Treasury Secretary Jack Lew announcing on Monday that his department planned to make a decision “in the very near future” about how to stem the inversion tide. Industry-watchers have said the threat of action from lawmakers could be holding some transactions up–like Hospira’s reported deal for the nutrition unit of French company Danone, which recently stalled.
 
But others–including pharma giant Pfizer–are pressing full steam ahead to snag a tax break. Earlier this week, company execs told Bernstein Research analyst Tim Anderson that without one, Pfizer can’t properly compete with overseas companies–meaning it’ll be on the lookout whether or not it can get former target AstraZeneca ($AZN) to come to the table.
 
By Carly Helfand
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach